Novo Nordisk (NVO.US) Wegovy oral medication is marketed in the US, starting at $149 per month for self-funded patients

The Zhitong Finance App learned that Novo Nordisk (NVO.US) said on Monday that starting January 5, it will launch two types of oral weight loss drug Wegovy to patients at their own expense in the US. The 1.5 mg and 4 mg dosage forms are priced at $149 per month. According to the company's official website, there are also two high-dose oral dosage forms — 9 mg and 25 mg — on the market on the same day, with a monthly price of $299.

The announcement also stated that the price of the 4 mg dosage will be raised to $199 per month starting April 15.

According to information, the US Food and Drug Administration (FDA) approved the launch of this oral medication on December 22 last year. This move injected new impetus into Novo Nordisk regaining an advantage in market competition with LLY.US (LLY.US).

The oral simeglutide tablets approved this time have the same active ingredients as injectable Wegovy and Ozempic, and are all sold under the Wegovy brand. It is worth mentioning that Novo Nordisk has previously launched Rybelsus, an oral simeglutide drug for type 2 diabetes.